This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Various				
Liver disease; diabetes	Not applicable	<i>In vitro</i> and rat studies suggest a 2,4-dinitrophenol analog could help treat nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. In normal rats, an analog of 2,4-dinitrophenol was less toxic than the parent compound. In rat models of NAFLD or type 2 diabetes, the analog decreased fasting plasma levels of glucose, insulin and triglycerides compared with vehicle. The compound also decreased hepatic production of very low-density lipoprotein (VLDL) and increased glucose tolerance without toxicity. Planned work includes IND-enabling studies of the analog.	Patented; available for licensing	Perry R.J. <i>et al. Cell Metab.</i> ; published online Nov. 5, 2013; doi:10.1016/j.cmet.2013.10.004 Contact: Gerald I. Shulman, Yale School of Medicine, New Haven, Conn. e-mail: gerald.shulman@yale.edu
SciBX 6(47); doi:10.1038/scibx.2013.1359				
Published online Dec. 12, 2013				